Kornimate/medical-research-clean huggingface dataset:
patient education for patients with back pain referred to physical therapy

Conditions: Low Back Pain

Summary: the purpose of this study is to evaluate patients with low back pain who are scheduled to begin physical therapy but have not yet had their first appointment to better understand their beliefs and attitudes and to evaluate the effects of an educational session about low back pain.

the investigators will conduct a randomized trial to examine the effectiveness of a patient education session provided prior to beginning physical therapy on outcomes of usual physical therapy for acute/sub-acute low back pain patients. the study compares two groups, one group will be treated with usual physical therapy with no pre-treatment education and the other group will also receive the pre-treatment. patients will be followed after 6 weeks and 3 months. physical therapy care is left to the discretion of the physical therapist in conjunction with the patient. outcomes will include pain and disability, and patients attitude and believes (pain catastrophizing, fear avoidance behavior). the overall hypothesis is that the additional educational treatment may address and improve pain, disability and fear.

Eligibility criteria:
inclusion criteria: * chief complaint of non-specific low back pain scheduled to receive outpatient physical therapy * age 18-60 * duration of current symptoms \< 8weeks * referred to physical therapy from a non-surgeon provider * no treatment received for low back pain in past year other than physician office visits. exclusion criteria: * diagnosis provided by the referral source indicating a specific pathoanatomical source for lbp including fracture, spondylolesthesis, ankylosing spondylitis, radiculopathy * any red flags in the patient's general medical screening questionnaire (i.e. tumor, metabolic diseases etc.).
addition of magnesium sulfate to caudal to prevent postoperative emergence agitation.

Conditions: Agitation; Pediatric Disorder

Summary: emergence agitation after sevoflurane anesthesia is still a problem needed to be solved.the aim of the study is to delineate the effect of caudal magnesium sulfate in children undergoing lower abdominal surgery to prevent postoperative emergence agitation.

emergency agitation is considered one of the postoperative complication after sevoflurane anesthesia.in the enrollment of this study,children undergoing lower abdominal surgery will be enrolled in one of two groups.bm group, receive caudal magnesium sulfate 50 mg beside the conventional bupivacaine in the caudal space in ,b group, addition of 1 ml of normal saline0.9% to bupivacine .monitoring of the postoperative emergence agitation by different emergence agitation scores with monitoring of sedation score.detection of expected postoperative complications as nausea and vomiting.

Eligibility criteria:
inclusion criteria: * children undergoing lower abdominal surgery for hernia repair/orchiopexy in ain shams university asa physical status i under sevoflurane anesthesia. * age from 1-6 years. exclusion criteria: * children with developmental delay * neurological disorder. * psychological disorder * difficult airway * hyperactive airway disease * contraindication to caudal block(sacral abnormality,bleeding disorder).

Keywords: sevoflurane pediatric lower abdominal surgery caudal magnesium sulfate magnesium sulfate causing adverse effects in therapeutic use agitation states as acute reaction to exceptional stress
vitamin d and microvascular function in postmenopausal women

Conditions: Menopause Related Conditions; Vitamin D Deficiency; Cardiovascular Diseases

Summary: many observational studies have demonstrated links between serum levels of 25-hydroxyvitamin d \[25(oh)d\] and cardiovascular risk (cvr) factors. microvascular dysfunction relates not only to cvr but also to metabolic disease. since cardiovascular disease (cvd) is the leading cause of death in postmenopausal women, it would be relevant to confirm this relationship. maybe further studies would show that the correction of hypovitaminosis d could minimize the cvr. our objective with this clinical trail is to analyze if vitamin d status is related to microvascular function and conventional cardiovascular risk (cvr) factors in postmenopausal women. for that we enrolled, in a pilot cross-sectional study, 39 non-smokers, low cvr postmenopausal women, with less than 10 years of hypoestrogenism and associations of 25(oh)d to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, homa-ir, parathormone and microvascular function, assessed by laser-doppler flowmetry at cutaneous site, were investigated.


Eligibility criteria:
inclusion criteria: women between 45-60 years with clinical/laboratory criteria of menopause and duration of hypoestrogenism \ 35 mu/ml and estradiol levels \<20 pg/ml. exclusion criteria: current smokers, body mass index (bmi) \>35 kg/m², systolic bp \>160 mmhg and or diastolic bp \> 100 mmhg, total cholesterol \>280 mg/dl, presence of t2d, renal dysfunction and or liver disease, clinical manifestations of coronary heart disease, and previous history of revascularization or cardiovascular event.

Keywords: menopause vitamin d microvascular circulation laser doppler flowmetry
efficacy and safety of intrathecal morphine for postoperative pain management following caesarean section

Conditions: Caesarean Section; Postoperative Pain

Summary: the goal of this clinical trial is to learn if morphine added to the spinal anaesthesia can improve postoperative pain treatment for patients undergoing caesarean section, without increasing the risk of serious adverse events in mother and baby. the main questions it aims to answer are: * is the treatment effective in preventing postoperative pain? * is the treatment safe for both mother and baby? participants will be given a normal spinal anaesthesia with addition of either morphine or sodium chloride (inactive substance). all participants will receive standard postoperative pain treatment, including morphine tablets as needed. researchers will collect data from the electronic medical record and ask the participants to fill out questionnaires about pain levels and possible side effects.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years * singleton pregnancy * scheduled for planned caesarean section performed under spinal anaesthesia * written informed consent exclusion criteria: * allergy to or contraindications towards trial medication * patients planned for postoperative epidural due to expected difficult postoperative pain management * patients planned for combined spinal-epidural as primary anaesthesia * inability to understand and read danish * previous inclusion in the trial

Keywords: caesarean section cesarean section cesarean delivery caesarean delivery postoperative pain intrathecal morphine spinal morphine
furst 2.0 cognitive pre-testing

Conditions: Huntington's Disease

Summary: the furst 2.0 scale is being developed as a patient reported outcome (pro) with information coming directly from the huntington's disease gene expansion carrier (hdgec) and companion through self-report. the purpose of this study is to identify real or potential comprehension or usage problems with questionnaire items or response options. through a process of structured cognitive de-briefing with hdgec participants and companions, independently, followed by qualitative analysis, the final phrasing of the individual items and response options for the scale will be generated. depending on the results of the first round of cognitive pre-testing, additional rounds of cognitive pre-testing may be required.


Eligibility criteria:
main criteria for inclusion: 1. hdgec participant must be a participant in enroll-hd (nct no.: nct01574053) 2. at least 18 years of age 3. must be fluent in english and had his primary education in english 4. must be willing and able to provide written informed consent pre-manifest hdgecs criteria 1-4, and: 1. cag length greater than or equal to 40 2. disease burden score greater than or equal to 250 (calculated by the equation: \[cagn-35.5\] x age) 3. uhdrs diagnostic confidence level (dcl) \< 3 4. at least five pre-manifest hdgec participants should have a companion who is willing to participate in this study and complete the scale independently. early-manifest (stage 1\&2) hdgecs criteria 1-4, and: 1. cag length greater than or equal to 36 2. dcl=4 3. uhdrs total functional capacity (tfc) ≥7 4. participants whose companion is willing to participate in this study and complete the scale independently main criteria for exclusion: 1. significant cognitive or any other impairment sufficient to interfere with study associated tasks as judged by the study investigator or the investigator's designee 2. currently participating in a clinical trial involving an investigational medicinal product

Keywords: huntington's disease functional rating scale cognitive pre-testing patient reported outcome (pro) hdgec participant at pre-manifest stage hdgec participant at early-manifest stage corresponding hdgec participant companion
stereotaxis computed tomography (ct) co-registration study

Conditions: Coronary Artery Disease

Summary: the stereotaxis niobe® ii magnetic navigation system (mns) is designed to direct and digitally control catheter and guidewire based therapeutic and diagnostic devices along complex trajectories within the heart and coronary vasculature. navigation using vectors acquired from the ct co-registration feature of navigant™ provides clinical benefits for percutaneous coronary intervention (pci) by decreasing the amount of contrast used during complex pci procedures.


Eligibility criteria:
inclusion criteria: * patients must be between 18-80 years of age * willing and able to provide prior written informed consent * patients present with a single bifurcated lesion or single non-cto complex lesion requiring pci. * able to be safely exposed to magnetic fields, such as magnetic resonance imaging (mri) * ct angiography performed prior to cardiac catheterization (must be performed \>48 hours prior to procedure to limit peri-procedural contrast use, but \<12 months prior to the procedure) exclusion criteria: * patients with a creatinine greater than 2.0 mg/dl * exclude patients whom in the investigator's opinion, are hemodynamically unstable on the day of the procedure. * untreatable allergy to contrast media * patients who have undergone ct angiography within 48 hours of index pci procedure * patients with chronic total occlusions (ctos) requiring intervention. * patients requiring treatment for lesions other than the single bifurcated or single non-cto complex lesion.

Keywords: percutaneous coronary intervention magnetic navigation computed tomography
clinical study on optimised removal of protein-bound uremic toxins with convective dialysis treatment.

Conditions: Chronic Renal Failure

Summary: patients will be treated with hemodiafiltration (hdf) in postdilution mode, as a control therapy, during 9 weeks. during week 5 the 1st intervention treatment, predilution hemofiltration (hf) or predilution hdf, will be performed as a midweek session. after 4 additional weeks of control therapy the other intervention treatment will be performed. samples will be taken during week 4, 5 and 9: from inlet blood flow (0, 30, 60, 120 and 240 min), from outlet blood flow and dialysate outflow (30, 60, 120 and 240 min).


Eligibility criteria:
inclusion criteria: * stable on hemodialysis \>= 6 months * of which presently on high-flux hd \>= 1 month * 18 years \< age \< 85 years * blood flow rate \>= 300ml/min exclusion criteria: * expected survival \< 1 year * expected transplant within \< 1 year * infectious diseases * pregnancy * chronic inflammation condition * treated with single needle dialysis * presently treated with hemodiafiltration or low-flux hemodiafiltration * expected intradialytic body weight gain \>= 4kg
electronic alert for acute kidney injury in geriatric wards

Conditions: Acute Kidney Injury

Summary: operating acute kidney injury electronic alert in geriatric wards; acute authenticity evaluation of acute kidney injury electronic alert; to explore the clinical value of electronic alert for acute kidney injury prevention and treatment in geriatric wards.


Eligibility criteria:
inclusion criteria: * age over 65 years old * diagnose of acute kidney injury by e-alert exclusion criteria: * baseline serum creatinine \> 4mg/dl * stage-5 chronic kidney disease or maintenance hemodialysis * kidney transplantation * amputation

Keywords: acute kidney injury alert geriatric wards
the effect of thiazide, amiloride and hypertonic saline on urinary biomarkers in healthy subjects

Conditions: Nephropathy

Summary: urinary biomarkers (u-nkcc2, u-enac-gamma and u-aqp2) reflects the activity of the sodium- and water channels in the human kidney. changes in the sodium-and water channel activity can be induced by blocking the sodium channels with diuretics in healthy subjects

1. urinary biomarkers (u-nkcc2, u-enac-gamma and u-aqp2) reflects the kidneys transport of sodium and water in the nephron. 2. changes in the sodium-and water channel activity is induced by blocking the ncc channels with thiazide and enac channels with amiloride and by intervention with hypertonic nacl the changes in sodium-and water channels are followed by changes in extracellular and intracellular fluids, central bloodpressure and the plasma concentration of vasoactive hormones. the purpose of this study is to investigate the changes in urinary biomarkers (u-nkcc2, u-enac-gamma and u-aqp2), extra- and intracellular fluid compartments, central bloodpressure and the plasma concentration of vasoactive hormones in healthy subjects under a) treatment with amiloride and thiazide at baseline and b) after and acute infusion with hypertonic saline. subjects will be examined on three examination days. four days prior to the examination days the subjects will consume a standard diet based on amount of sodium and calories and randomized to treatment with either thiazide, amiloride or placebo twice daily for 5 days. on the examination days the subjects receive an infusion with hypertonic saline. renal function is measured by renal clearance of 51cr-edta. urinary biomarkers (u-nkcc2, u-enac-gamma and u-aqp2) will be measured to evaluate the activity of water- and sodium channels in the nephron, changes in fluid compartments are measured by body composition monitor. central blood pressure is measured by sphygmocor.

Eligibility criteria:
inclusion criteria: * healthy males and females * age 18-45 * bmi range 18,5-30,0 kg/m2 exclusion criteria: * hypertension (i.e. ambulatory bp \> 130 mmhg systolic or/and \> 80 mmhg diastolic) * history or clinical significant signs of heart, lung, liver, kidney, endocrine, brain or neoplastic * disease. * alcohol abuse * drug abuse * smoking * pregnancy or nursing * blood donation within a month prior to examination * medical treatment apart from oral contraception abnormal blood samples, -ecg and -urine dipstick, drug abuse, alcohol abuse, pregnancy, medication

Keywords: nephrology sodium-channels water-channels bcm central blood pressure
phase ii study of tpa plus dexamethasone & cmt in hematologic malignancies

Conditions: Leukemia

Summary: this phase ii trial is studying the side effects and how well giving tetradecanoylphorbol acetate together with dexamethasone and choline magnesium trisalicylate works in treating patients with relapsed or refractory acute myeloid leukemia.


Eligibility criteria:
inclusion criteria * must have a histologically documented relapsed/refractory aml for which there is no standard therapy that has been demonstrated to have curative or palliative potential. * ecog performance status of 0-2. * must be 18 years or older. * estimated life expectancy \> 1 month. * laboratory data: * total bilirubin ≤ 1.5 x upper limit of normal unless due to gilbert's syndrome * serum creatinine ≤ 2.0 mg/dl * ast ≤ 3.0 x upper limit of normal * cardiac ejection fraction \> 40% * fev1.0 \> 50% predicted * prior therapy: \> 3 weeks since chemotherapy, biological therapy or radiation; anticipated maximum hematological improvement since last dose of chemotherapy. (concurrent hydroxyurea administration will be allowed to control wbc count, platelet count, or symptoms). * no active infections. * negative pregnancy test for women of childbearing potential. * no uncontrolled psychiatric illness or medical illness that the principal investigator feels will compromise the patient's tolerance of the study medication. * must provide informed consent. exclusion criteria * patients with an allergy to proton pump inhibitors, required for gi prophylaxis; or salicylates are excluded. * pregnant or lactating women * age \<18 years. because no dosing or adverse event data are currently available on the use of tpa alone or in combination with dexamethasone in patients \< 18 years of age, children are excluded from this study but will be eligible for future pediatric phase ii combination trials. * the effects of tpa on the developing human fetus are unknown. for this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 10 weeks after. should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. should the female partner of a participant in this study become pregnant or suspect she is pregnant during this study, the pi of this study will be available to provide advice about further medical/obstetric care/referral for the female partner. * patients with active cns involvement (documented by radiographic lesions and/or malignant cells in the csf) will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. * patients with treatment of any other investigational drug within the last 30 days prior to entering the study.

Keywords: acute myelogenous leukemia relapsed aml refractory aml
monitoring of cerebral and abdominal tissue oxygen saturation in neonates

Conditions: Establish the Incidence Rate of Abdominal and Cerebral Hyperoxemia and Hypoxemia Events in Neonates at Birth

Summary: near-infrared spectroscopy (nirs) functions in a manner similar to pulse oximetry, using the difference in absorptive qualities of oxy- and deoxyhemoglobin to infrared light to quantify the percent saturation. there is also available evidence shows that tissue oximetry is sensitive and has a quicker response to physiological derangement, such as bradycardia, in preterm newborns. additionally, it is demonstrated that reduced postoperative cerebral tissue oxygenation index variability in neonatal survivors of congenital heart disease surgery with poor neurodevelopmental outcomes. the safeboosc phase ii randomized clinical trial hypothesizes that the burden of hypo- and hyperoxia can be reduced, and consequently the risk of brain injury, by the combined use of close monitoring of the cerebral rsto2 and an evidence-based treatment guideline to correct deviations in rsto2 outside a predefined target range. in this study, we will monitor 2 different tissue beds including cerebral and abdominal somatic tissue rsto2 and spo2 in neonates. further research is needed to investigate clinical implications for using this measure to drive therapeutic interventions.


Eligibility criteria:
inclusion criteria: 1. term infants (37-42 weeks of gestation) 2. elective cesarean section after pregnancy exclusion criteria: 1. thick hair that makes good measurements difficult/impossible 2. obvious malformations or syndrome 3. complications in relation to the cesarean section
hydrophilic acrylic intraocular lens

Conditions: Cataract Extraction

Summary: the purpose of this study is to evaluate the safety and efficacy of hydrophilic acrylic intraocular lens after cataract surgery


Eligibility criteria:
inclusion criteria: * the patient is in good general and ocular health, having a vision-reducing cataract in the intended operative eye * the patient is willing and able to complete all required postoperative visits. * the patient is willing to sign a statement of informed consent. preoperative exclusion criteria: * the patient is under the age of 18 * the patient has had prior intraocular surgery in the operative eye. * the patient has systemic diseases with ocular manifestations (e.g. diabetes, complications of immune deficiency syndrome), which may contribute to postoperative confounding of data interpretation. * the patient's worst seeing eye is 20/70 or worse. * the patient has multiple surgical procedures at the time of implant. * the patient has chronic use of steroids, immunosuppressive and/or antineoplastic agents. * the patient has acute infection, inflammation of the eye. * iris atrophy * proliferative diabetic retinopathy. * chronic, medically uncontrolled glaucoma * chronic uveitis, iritis, iridocyclitis or rubeosis of the lids * rubella, traumatic or congenital/developmental cataract. * severe retinal pathology (e.g. retinal tear, detachment, etc). operative patient exclusion criteria * capsular rupture * vitreous loss * hyphema * zonular disinsertion * surgical complications- in the event of a complication during surgery, the surgeon should decide whether the stability of the hydrophilic acrylic lens would be compromised by the complication, e.g. in the event of zonular damage of major capsule rupture. if the lens stability would be compromised, the hydrophilic acrylic lens should not be implanted and the surgeon should make arrangements to implant an alternative lens.

Keywords: cataract extraction intraocular lens hydrophilic acrylic
effect of intraoperative nefopam on acute pain after remifentanil based anesthesia

Conditions: Cholecystitis

Summary: many anesthesiologists use the remifentanil for reducing a surgical pain and stabilizing a vital sign. however, this drug induce postoperative hyperalgesia. nowadays, many studies report that low-dose ketamine prevents the opioid-induces hyperalgesia. nefopam,which is non-opioid analgesic, has similar mechanism with ketamine. it will be helpful for postoperative pain control, and reduce the needs of opioid.


Eligibility criteria:
inclusion criteria: * patient who scheduled laparoscopic cholecystectomy under general anesthesia * american society of anesthesiologist(asa) class i or ii * adult patient (age 20 - 65) exclusion criteria: * patient who has liver disease * patient who has kidney disease * patient who has diabetes mellitus(dm) or heart disease * patient who takes opioid or beta-blocker * patient who has airway disease * patient who has allergy with the drug